Zobrazeno 1 - 10 of 39 pro vyhledávání: '"Naohisa Matsumoto"'
1
Akademický článek
Anti‐Müllerian hormone type II receptor protein expression in non‐small cell lung cancer and the effect of AMH/AMHR2 signaling on cancer cell proliferation
Autor: Yoshika Koinuma, Yoichiro Mitsuishi, Wira Winardi, Moulid Hidayat, Aditya Wirawan, Daisuke Hayakawa, Koichiro Kanamori, Naohisa Matsumoto, Takuo Hayashi, Naoko Shimada, Ken Tajima, Kazuya Takamochi, Fumiyuki Takahashi, Kenji Suzuki, Kazuhisa Takahashi
Publikováno v: Thoracic Cancer, Vol 15, Iss 29, Pp 2090-2099 (2024)
Abstract Background Non‐small cell lung cancer (NSCLC) is the leading cause of cancer‐related deaths worldwide despite advances in cancer therapeutics. In several gynecological cancers, anti‐Müllerian hormone receptor type 2 (AMHR2) mediates A
Externí odkaz: https://doaj.org/article/82d06edb6975422788f4f5db05f9e50a
Zobrazit plný text záznamu
2
Akademický článek
The role of comprehensive analysis with circulating tumor DNA in advanced non‐small cell lung cancer patients considered for osimertinib treatment
Autor: Naoko Sueoka‐Aragane, Chiho Nakashima, Hironori Yoshida, Naohisa Matsumoto, Kentaro Iwanaga, Noriyuki Ebi, Akihiro Nishiyama, Kazuhiro Yatera, Shoichi Kuyama, Minoru Fukuda, Sunao Ushijima, Hitomi Umeguchi, Daijiro Harada, Kosuke Kashiwabara, Takayuki Suetsugu, Nobukazu Fujimoto, Fumihiro Tanaka, Hidetaka Uramoto, Chiharu Yoshii, Katsumi Nakatomi, Genju Koh, Nobuhiko Seki, Keisuke Aoe, Kaname Nosaki, Koji Inoue, Ayako Takamori, Atsushi Kawaguchi
Publikováno v: Cancer Medicine, Vol 10, Iss 12, Pp 3873-3885 (2021)
Abstract Background EGFR mutations are good predictive markers of efficacy of EGFR tyrosine kinase inhibitors (EGFR‐TKI), but whether comprehensive genomic analysis beyond EGFR itself with circulating tumor DNA (ctDNA) adds further predictive or pr
Externí odkaz: https://doaj.org/article/9fdb0934bf3d40bbb7a19d2b98a77955
Zobrazit plný text záznamu
3
Akademický článek
Impact of the generation of EGFR‐TKIs administered as prior therapy on the efficacy of osimertinib in patients with non‐small cell lung cancer harboring EGFR T790M mutation
Autor: Yosuke Miyashita, Ryo Ko, Naoko Shimada, Yoichiro Mitsuishi, Keita Miura, Naohisa Matsumoto, Tetsuhiko Asao, Takehito Shukuya, Rina Shibayama, Ryo Koyama, Kazuhisa Takahashi
Publikováno v: Thoracic Cancer, Vol 12, Iss 3, Pp 329-338 (2021)
Abstract Background There are few studies that directly compare the effects of osimertinib on patients with non‐small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) T790M mutation between the generation of prior EGFR tyr
Externí odkaz: https://doaj.org/article/ab4352ca40014857bcdf4cb0d2d1a7e9
Zobrazit plný text záznamu
4
Akademický článek
Activation of insulin‐like growth factor‐1 receptor confers acquired resistance to osimertinib in non‐small cell lung cancer with EGFR T790M mutation
Autor: Daisuke Hayakawa, Fumiyuki Takahashi, Yoichiro Mitsuishi, Ken Tajima, Moulid Hidayat, Wira Winardi, Hiroaki Ihara, Koichiro Kanamori, Naohisa Matsumoto, Tetsuhiko Asao, Ryo Ko, Takehito Shukuya, Kazuya Takamochi, Takuo Hayashi, Yoshiyuki Suehara, Ikuko Takeda Nakamura, Toshihide Ueno, Shinji Kohsaka, Hiroyuki Mano, Kazuhisa Takahashi
Publikováno v: Thoracic Cancer, Vol 11, Iss 1, Pp 140-149 (2020)
Abstract Background Osimertinib (AZD9291) is a third‐generation EGFR‐tyrosine kinase inhibitor (TKI) that selectively inhibits the activating EGFR mutation and T790M mutation, and is currently used globally to treat EGFR‐mutant non‐small cell
Externí odkaz: https://doaj.org/article/7d68caf12b94489a9d22c92066cd0c8d
Zobrazit plný text záznamu
5
Akademický článek
Anesthetic management of a patient with sodium-channel myotonia: a case report
Autor: Naohisa Matsumoto, Rei Nishimoto, Yoshikazu Matsuoka, Yoshimasa Takeda, Hiroshi Morimatsu
Publikováno v: JA Clinical Reports, Vol 5, Iss 1, Pp 1-4 (2019)
Abstract Background Sodium-channel myotonia (SCM) is a nondystrophic myotonia, characterized by pure myotonia without muscle weakness or paramyotonia. The prevalence of skeletal muscle channelopathies is approximately 1 in 100,000, and the prevalence
Externí odkaz: https://doaj.org/article/22b703360d16444d938c9913f2d73e22
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje